Land-use effects on local biodiversity in tropical forests vary between continents

The file attached is the Published/publisher’s pdf version of the article

A pair of sub-Neptunes transiting the bright K-dwarf TOI-1064 characterized with CHEOPS

We report the discovery and characterization of a pair of sub-Neptunes transiting the bright K-dwarf TOI-1064 (TIC 79748331), initially detected in the Transiting Exoplanet Survey Satellite (TESS) photometry. To characterize the system, we performed and retrieved the CHaracterising ExOPlanets Satellite (CHEOPS), TESS, and ground-based photometry, the High Accuracy Radial velocity Planet Searcher (HARPS) high-resolution spectroscopy, and Gemini speckle imaging. We characterize the host star and determine T-eff,T-* = 4734 +/- 67 K, R-* = 0.726 +/- 0.007 R-circle dot, and M-* = 0.748 +/- 0.032 M-circle dot. We present a novel detrending method based on point spread function shape-change modelling and demonstrate its suitability to correct flux variations in CHEOPS data. We confirm the planetary nature of both bodies and find that TOI-1064 b has an orbital period of P-b = 6.44387 +/- 0.00003 d, a radius of R-b = 2.59 +/- 0.04 R-circle plus, and a mass of M-b = 13.5(-1.8)(+1.7) M-circle plus, whilst TOI-1064 c has an orbital period of P-c = 12.22657(-0.0)(0004)(+0.00005) d, a radius of R-c = 2.65 +/- 0.04 R-circle plus, and a 3 sigma upper mass limit of 8.5 M-circle plus. From the high-precision photometry we obtain radius uncertainties of similar to 1.6 per cent, allowing us to conduct internal structure and atmospheric escape modelling. TOI-1064 b is one of the densest, well-characterized sub-Neptunes, with a tenuous atmosphere that can be explained by the loss of a primordial envelope following migration through the protoplanetary disc. It is likely that TOI-1064 c has an extended atmosphere due to the tentative low density, however further radial velocities are needed to confirm this scenario and the similar radii, different masses nature of this system. The high-precision data and modelling of TOI-1064 b are important for planets in this region of mass-radius space, and it allow us to identify a trend in bulk density-stellar metallicity for massive sub-Neptunes that may hint at the formation of this population of planets

Failure of the Patellar Tendon with the Patella Everted versus Noneverted in a Matched-Pair Cadaver Model

Avoidance of patellar eversion during total knee arthroplasty may help to prevent injury to the patellar tendon. The purpose of this study was to compare the load-to-failure of the everted versus the noneverted patella in a cadaveric model. Fourteen cadaver knees (seven pairs) were loaded to failure with the patella everted in one knee and not everted in the other. Mean load-at-ultimate failure in the patella-everted group was 1,111 ± 572 N, and in the patella-noneverted group was 1,621 ± 683 N (p = 0.01). Additionally, loads-at-initial-partial failure were lower (p = 0.04) in the patella-everted compared to the patella-noneverted group, 573 ± 302 N versus 1,115 ± 358 N, respectively. A partial failure of the patellar tendon occurred in 100% of the everted specimens, whereas only 57% of the noneverted specimens had partial failure. These findings suggest patella eversion may lead to failure of the patellar insertion at lower loads than when the patella is not everted

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

BACKGROUND: Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observation randomised trials demonstrated that a treatment benefit was observed only in patients with an ulcerated melanoma without palpable nodes (hazard ratio [HR] for recurrence-free survival [RFS] was 0.69). This was confirmed by a meta-analysis of 15 adjuvant IFN trials (HR: 0.79). PATIENTS AND METHODS: In the EORTC 18081 trial, sentinel node-negative stage II patients with an ulcerated primary melanoma were 1:1 randomised between pegylated (PEG)-IFNα-2b at 3 μg/kg/week subcutaneously and observation, for 2 years, or until disease recurrence or unacceptable toxicity in spite of dose adjustments to maintain an Eastern Cooperative Oncology Group performance status of 0 or 1. Main end-point was RFS. Secondary end-points included distant metastasis-free survival (DMFS), overall survival, and safety (EudraCT Number: 2009-010273-20). RESULTS: Between February 2013 and January 2017, only 112 patients were randomised, 56 in each arm. The trial was stopped early for lack of recruitment. At a 3.4-year median follow-up, the estimated HR for the PEG-IFNα-2b group compared with the observation group regarding RFS was 0.66 (95% confidence interval [CI]: 0.32-1.37), and the 3-year RFS rate was 80.0% (95% CI: 65.7-88.8%) and 72.9% (95% CI: 58.3-83.0%), respectively. DMFS was prolonged: HR: 0.39 (95% CI: 0.15-0.97), and the 3-year DMFS rate was 90.6% (95% CI: 78.9-96.0%) vs 76.4% (95% CI: 62.1-85.9%). One patient in the PEG-IFNα-2b group died compared with 4 in the observation group. Fifty-four patients started PEG-IFNα-2b treatment, 16 (29%) completed 2 years of treatment, 2 (4%) stopped due to recurrence, 23 (43%) due to toxicity and 14 (25%) due to other reasons. CONCLUSIONS: The EORTC 18081 PEG-IFNα-2b randomised trial, observed a similar HR (0.69) for RFS as the previous EORTC trials (0.69). In countries without access to new drugs, adjuvant (PEG)-IFNα-2b treatment is an option for patients with ulcerated melanomas without palpable nodes.status: publishe